A new economic analysis from a team of U-M researchers reports that investing in updated vaccination for adults across all ages, especially those in their late 50s to early 60s, would be worth it, relative to the money spent by U.S. insurers and government healthcare programs. Widespread vaccination lowers rates of hospitalizations, critical illness, long COVID, and deaths. The U-M team presented this analysis to the Center for Disease Control on September 12th.
